About Surrozen Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.surrozen.com
Frequently Asked Questions
What is the 52-week range for SRZN?
The 52-week high is $37.83 and the 52-week low is $11.39.
What is the P/E ratio for SRZN?
The P/E ratio data is currently unavailable.
What is the dividend yield for SRZN?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 58.23%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -2885.33%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.51.
Analyst Recommendation Trends
Wall Street analyst consensus for SRZN over the last few months:
Latest SRZN News
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
First patient expected to be dosed in the DUET study in the fourth quarter of 2026 Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross proceeds SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic
Unusual volume stocks are being observed in Friday's session.
Unusual volume stocks are being observed in Friday's session.
Scholastic Posts Downbeat Q1 Results, Joins Legacy Education, Zscaler And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures rose, but Scholastic plunged 9.9% after missing Q1 loss and sales estimates; several other stocks also fell premarket.
HC Wainwright & Co. Maintains Buy on Surrozen, Raises Price Target to $54
HC Wainwright & Co. analyst Matthew Caufield maintains Surrozen (NASDAQ:SRZN) with a Buy and raises the price target from $44 to $54.
Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
INLIF shares jumped 78% after H1 FY26 revenue rose 26%, gross profit surged 159% and net income turned positive; other premarket movers varied.
Keep an eye on the top gainers and losers in Thursday's session.
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Which stocks are moving on Thursday?
Wondering how the US markets performed in the middle of the day on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.
The market is filled with gapping stocks in Thursday's session.
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares increased by 162.4% to $6.01 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. Surrozen (NASDAQ:SRZN) stock
Wondering what's happening in today's pre-market session?
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Crude Oil Rises Over 4%; Darden Earnings Miss Views
U.S. stocks fell Thursday: Dow -0.7%, S&P 500 -0.46%, Nasdaq -0.7%. Oil jumped 4.4%; Darden missed estimates, while APUS surged 163%.
Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy
Surrozen submitted an IND application to the FDA for SZN-8141 to treat diabetic macular edema, with trial data expected in late 2027.
Dow Tumbles Over 100 Points; US Jobless Claims Fall to 197,000
U.S. stocks fell Thursday as tech slid; jobless claims beat estimates. Oil rose, while APUS surged 245% and BENF plunged 33%.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Profusa (NASDAQ:PFSA) stock increased by 112.5% to $4.36 during Thursday's pre-market session. The company's market cap stands at $1.2 million. GlucoTrack (NASDAQ:GCTK) stock rose 96.55% to $3.99. The
Surrozen, Inc. (SRZN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Surrozen, Inc. (SRZN) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 1:50 PM EDTCompany ParticipantsCraig Parker - CEO,...
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration seeking to evaluate SZN-8141, a bifunctional Wnt agonist and vascular endo
Surrozen Submits IND Application To FDA Seeking To Evaluate SZN-8141, Bifunctional Wnt Agonist And Vascular Endothelial Growth Factor Antagonist Antibody, For Treatment Of Diabetic Macular Edema
Surrozen, Inc. (Surrozen or the Company) (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-22 | TCG Crossover GP II, LLC | -162,500 | $21.25 | $3,453,125 |
| 2026-07-22 | TCG Crossover GP II, LLC | -162,500 | $21.25 | $3,453,125 |
| 2026-06-15 | Maleki Andrew Pedrum | +607 | $19.01 | $11,539 |
| 2026-06-15 | Li Yang | +1,666 | $8.11 | $13,511 |
| 2026-06-15 | Parker Craig C | +1,622 | $8.11 | $13,154 |
| 2026-06-15 | Williams Charles O | +1,666 | $8.11 | $13,511 |
| 2026-05-13 | Kutzkey Tim | +5,550 | - | - |
| 2026-05-13 | Haak-Frendscho Mary | +5,550 | - | - |
| 2026-05-13 | CHAI CHRISTOPHER Y | +5,550 | - | - |
| 2026-05-13 | BJERKHOLT ERIC | +5,550 | - | - |
| 2026-05-13 | Rothenberg Mace | +5,550 | - | - |
| 2026-05-13 | Berkenblit Anna | +5,550 | - | - |
| 2026-05-13 | WOODHOUSE DAVID J | +5,550 | - | - |
| 2026-05-04 | Parker Craig C | -4,524 | $33.3328 | $150,798 |
| 2026-05-04 | Li Yang | -1,584 | $33.3328 | $52,799 |
| 2026-05-04 | Williams Charles O | -2,036 | $33.3328 | $67,866 |
| 2026-05-01 | Parker Craig C | -12,500 | - | - |
| 2026-05-01 | Parker Craig C | +12,500 | - | - |
| 2026-05-01 | Li Yang | -4,375 | - | - |
| 2026-05-01 | Li Yang | +4,375 | - | - |
| 2026-05-01 | Williams Charles O | -5,625 | - | - |
| 2026-05-01 | Williams Charles O | +5,625 | - | - |
| 2026-03-31 | Li Yang | -1,666 | - | - |
| 2026-03-24 | TCG Crossover Fund II, L.P. | +53,329 | $24.6931 | $1,316,858 |
| 2026-03-24 | TCG Crossover Fund II, L.P. | +53,329 | $24.6931 | $1,316,858 |
| 2026-03-23 | TCG Crossover Fund II, L.P. | +7,611 | $24.8999 | $189,513 |
| 2026-03-23 | TCG Crossover Fund II, L.P. | +7,612 | $24.8999 | $189,538 |
| 2026-03-16 | TCG Crossover Fund II, L.P. | +595 | $24.9857 | $14,866 |
| 2026-03-16 | TCG Crossover Fund II, L.P. | +595 | $24.9857 | $14,866 |
| 2026-03-13 | TCG Crossover Fund II, L.P. | +17,716 | $24.8769 | $440,719 |
| 2026-03-13 | TCG Crossover Fund II, L.P. | +17,717 | $24.8769 | $440,744 |
| 2026-03-12 | TCG Crossover Fund II, L.P. | +6,187 | $24.9851 | $154,583 |
| 2026-03-12 | TCG Crossover Fund II, L.P. | +6,187 | $24.9851 | $154,583 |
| 2026-02-17 | Li Yang | +100,950 | - | - |
| 2026-02-17 | Li Yang | +100,950 | - | - |
| 2026-02-17 | Parker Craig C | +242,200 | - | - |
| 2026-02-17 | Parker Craig C | +242,200 | - | - |
| 2026-02-17 | Williams Charles O | +102,900 | - | - |
| 2026-02-17 | Williams Charles O | +102,900 | - | - |
| 2026-02-12 | TCG Crossover Fund II, L.P. | +546 | $23.8625 | $13,029 |
| 2026-02-12 | TCG Crossover Fund II, L.P. | +547 | $23.8625 | $13,053 |
| 2026-02-11 | TCG Crossover Fund II, L.P. | +8,881 | $23.575 | $209,370 |
| 2026-02-11 | TCG Crossover Fund II, L.P. | +8,882 | $23.575 | $209,393 |
| 2026-02-03 | TCG Crossover Fund II, L.P. | +2,177 | $21.94 | $47,763 |
| 2026-02-03 | TCG Crossover Fund II, L.P. | +2,178 | $21.94 | $47,785 |
| 2026-02-02 | TCG Crossover Fund II, L.P. | +365 | $21.38 | $7,804 |
| 2026-02-02 | TCG Crossover Fund II, L.P. | +366 | $21.38 | $7,825 |
| 2026-01-30 | TCG Crossover Fund II, L.P. | +2,135 | $21.39 | $45,668 |
| 2026-01-30 | TCG Crossover Fund II, L.P. | +2,136 | $21.39 | $45,689 |
| 2026-01-23 | Williams Charles O | +500 | - | - |
| 2026-01-20 | Kutzkey Tim | +9,568 | $19.5999 | $187,532 |
| 2026-01-20 | Kutzkey Tim | +8,484 | $19.5999 | $166,286 |
| 2026-01-20 | Svennilson Peter | +9,568 | $19.5999 | $187,532 |
| 2026-01-20 | Svennilson Peter | +8,484 | $19.5999 | $166,286 |
| 2026-01-16 | Kutzkey Tim | +1,358 | $20 | $27,160 |
| 2026-01-16 | Kutzkey Tim | +1,204 | $20 | $24,080 |
| 2026-01-16 | Svennilson Peter | +1,358 | $20 | $27,160 |
| 2026-01-16 | Svennilson Peter | +1,204 | $20 | $24,080 |
| 2026-01-15 | Kutzkey Tim | +6,303 | $19.889 | $125,360 |
| 2026-01-15 | Kutzkey Tim | +5,590 | $19.889 | $111,180 |
| 2026-01-15 | Svennilson Peter | +6,303 | $19.889 | $125,360 |
| 2026-01-15 | Svennilson Peter | +5,590 | $19.889 | $111,180 |
| 2026-01-14 | Kutzkey Tim | +2,927 | $19.9883 | $58,506 |
| 2026-01-14 | Kutzkey Tim | +2,596 | $19.9883 | $51,890 |
| 2026-01-14 | Svennilson Peter | +2,927 | $19.9883 | $58,506 |
| 2026-01-14 | Svennilson Peter | +2,596 | $19.9883 | $51,890 |
| 2026-01-13 | Kutzkey Tim | +6,609 | $19.8041 | $130,885 |
| 2026-01-13 | Kutzkey Tim | +5,861 | $19.8041 | $116,072 |
| 2026-01-13 | Svennilson Peter | +6,609 | $19.8041 | $130,885 |
| 2026-01-13 | Svennilson Peter | +5,861 | $19.8041 | $116,072 |
| 2026-01-06 | Kutzkey Tim | +8,003 | $19.8872 | $159,157 |
| 2026-01-06 | Kutzkey Tim | +7,097 | $19.8872 | $141,139 |
| 2026-01-06 | Svennilson Peter | +8,003 | $19.8872 | $159,157 |
| 2026-01-06 | Svennilson Peter | +7,097 | $19.8872 | $141,139 |
| 2026-01-05 | Li Yang | -1,118 | $19.8652 | $22,209 |
| 2026-01-05 | Williams Charles O | -1,566 | $19.8652 | $31,109 |
| 2026-01-02 | Li Yang | -2,500 | - | - |
| 2026-01-02 | Li Yang | +2,500 | - | - |
| 2026-01-02 | Williams Charles O | -3,500 | - | - |
| 2026-01-02 | Williams Charles O | +3,500 | - | - |
| 2025-12-15 | Li Yang | +1,666 | $8.11 | $13,511 |
| 2025-12-15 | Parker Craig C | +1,553 | $8.11 | $12,595 |
| 2025-12-15 | Williams Charles O | +1,666 | $8.11 | $13,511 |
| 2025-12-05 | COLUMN GROUP III-A, LP | +16,381 | $19.5409 | $320,099 |
| 2025-12-05 | COLUMN GROUP III-A, LP | +14,503 | $19.5409 | $283,402 |
| 2025-12-05 | Kutzkey Tim | +16,381 | $19.5409 | $320,099 |
| 2025-12-05 | Kutzkey Tim | +14,503 | $19.5409 | $283,402 |
| 2025-12-04 | COLUMN GROUP III-A, LP | +2,791 | $17.347 | $48,415 |
| 2025-12-04 | COLUMN GROUP III-A, LP | +2,475 | $17.347 | $42,934 |
| 2025-12-04 | Kutzkey Tim | +2,791 | $17.347 | $48,415 |
| 2025-12-04 | Kutzkey Tim | +2,475 | $17.347 | $42,934 |
| 2025-11-13 | Kutzkey Tim | +167,307 | $12.65 | $2,116,434 |
| 2025-11-13 | Kutzkey Tim | +148,150 | $12.65 | $1,874,098 |
| 2025-11-13 | COLUMN GROUP III-A, LP | +167,307 | $12.65 | $2,116,434 |
| 2025-11-13 | COLUMN GROUP III-A, LP | +148,150 | $12.65 | $1,874,098 |
| 2025-11-12 | Maleki Andrew Pedrum | +50,000 | - | - |